BackgroundPatients with diabetes mellitus are at an increased risk for adverse clinical events following percutaneous coronary interventions (PCI).However, the clinical impact of diabetes mellitus (DM) on second-generation drug-eluting stent (DES) implantation is not well-known.The aim of the current analysis was to examine the clinical impact of DM on clinical outcomes and the time sequence of associated risks in patients treated with second-generation DES.MethodsUsing patient-level data from two stent-specific, all-comer, prospective DES registries, we evaluated 1,913 patients koleston 55/44 who underwent PCI with second-generation DES between Feb 2009 and Dec 2013.The primary outcomes assessed were two-year major cardiac adverse events (MACE), composite endpoints of death from any cause, myocardial infarction (MI), and any repeat revascularization.
We classified 0-1 year as the early period and 1-2 years as the late period.Landmark analyses were performed according to diabetes mellitus status.ResultsThere were 1,913 patients with 2,614 lesions included in the pooled dataset.The median duration of clinical follow-up in the overall population was 2.0 years (interquartile range 1.
9-2.1).Patients with DM had more cardiovascular risk factors than patients without DM.In multivariate analyses, the presence of DM and renal failure were strong predictors of MACE and target-vessel revascularization (TVR).After inverse probability of treatment weighting (IPTW) analyses, patients with DM had significantly increased rates of 2-year MACE (HR 2.
07, 95% CI; 1.50-2.86; P ConclusionsIn the second-generation DES era, the clinical impact of DM significantly increased the 2-year event rate of MACE, mainly caused by clinical events in the early period (0-1 year).Careful observation of patients with DM is advised s2720 in the early period following PCI with second-generation DES.